Dr. Ahmed ElSobky, Chairman of Egypt Healthcare Authority, witnessed the signing of a Memorandum of Understanding with Merck Pharmaceuticals during the fifth annual forum of the authority.
Representing the Healthcare Authority was Dr. Amir El-Telwany, Executive Director of Egypt Healthcare Authority, while Dr. Sherif El-Seddawy, General Manager and Managing Director of Merck Egypt Pharmaceuticals, represented Merck Egypt.
ElSobky explained that the memorandum aims to enhance the strategic partnership between the two parties to improve the management of thyroid diseases, focusing on hypothyroidism.
He emphasised the importance of new partnerships, which are a strategic step towards developing the healthcare system in Egypt.
He expressed pride in the partnerships that open new horizons for providing high-quality healthcare services to citizens, affirming that the authority’s vision is based on enhancing technology and innovation to achieve sustainable healthcare and strengthen Egypt’s position as a leader in the healthcare field.
El-Seddawy explained that the memorandum aims to develop a comprehensive treatment protocol over three years, particularly focusing on managing hypothyroidism to achieve a significant improvement in patient health through three main axes:
-Expanding the scope of diagnosis by early detection of cases and providing necessary medical care in a timely manner.
-Empowering medical staff by implementing training programmes for doctors in various specialties, particularly internal medicine and general practice, in the first phase of Universal health insurance provinces, equipping them with the latest knowledge and skills needed to diagnose and treat thyroid diseases.
-Raising public awareness through launching intensive awareness campaigns across various social media platforms, in addition to printed campaigns, to highlight the importance of early detection of hypothyroidism and its impact on public health.
This aims to ensure the provision of consistent and high-quality healthcare for all patients.
In this regard, Egypt Healthcare Authority aims to develop the treatment protocol to ensure the provision of consistent and high-quality healthcare for all patients.
Merck is one of the oldest pharmaceutical companies in the world, founded in the city of Darmstadt, Germany, in 1668. Over more than 350 years, Merck has expanded to become a leading global force in science and technology.
Merck currently operates in about 65 countries worldwide, employing around 63,000 people, reflecting its commitment to providing innovative solutions that meet the needs of patients and communities everywhere.
Merck’s areas of work include three fields: life sciences, healthcare, and electronics.
Life sciences: Development of biotechnology and laboratory and manufacturing equipment.
Healthcare: Development of drugs and treatments, research in diseases, providing healthcare to patients.
Electronics: Manufacturing electronic materials for the semiconductor industry.
Merck’s journey in Egypt has extended for more than six decades, starting in 1957 with the establishment of a scientific office representing the parent company in Germany.
Over the years, this beginning evolved into an Egyptian company affiliated with the global Merck Group in 2007. Since then, Merck has significantly contributed to the development of the healthcare sector in Egypt.
Merck Egypt offers a wide range of therapeutic solutions in vital areas such as Cardiometabolic Care, Endocrinology, Fertility, Oncology, and Neurology.
